Orrin Devinsky

Engage Therapeutics, Inc. engages in the development of rescue therapy for uncontrolled epileptic seizures. The company was founded by Gregory T. Mayes III and Jouko Isojarvi in 2017 and is headquartered in Summit, NJ.

Silver Spike Acquisition Corp. operates as a blank check company. The firm intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Scott Gordon on June 7, 2019 and is headquartered in New York, NY.

Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA.

Silver Spike Acquisition Corp. II is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 2, 2020 and is headquartered in New York, NY.

Silver Spike III Acquisition Corp. operates as a special purpose acquisition corporation. Its objective is effecting, directly or indirectly, an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, share exchange, asset acquisition, share purchase, and reorganization. The company was founded on March 22, 2021 and is headquartered in New York, NY.

Silver Spike Capital LLC provides investment services. The company was founded by Scott Gordon in 2019 and is headquartered in New York. NY.

Silver Spike Sponsor III LLC provides investment services. The private company is based in New York, NY.

Tevard Biosciences, Inc. is a biotechnology company based in Cambridge, MA. Tevard Biosciences is focused on developing trna-based and other modulating therapies to cure a broad range of genetic diseases. The company is advancing the use of its novel suppressor trna, enhancer trna, and mrna amplifier platforms in neurological disorders, heart disease, and muscular dystrophies. The company was founded in 2017 by Warren Burt Lammert, Harvey F. Lodish, Daniel Fischer, and Jeffrey Coller. Daniel Fischer has been the CEO since 2017.

Regel Therapeutics Inc. develops a proprietary technology platform related to gene therapy. The company is based in Cambridge, MA. The company was founded in 2020 by Navneet Matharu, Jordane Dimidschstein, Steven B. Ruchefsky, Michael Jasulavic, Orrin Devinsky. Steven B. Ruchefsky has been the CEO since 2020.